Viking Therapeutics Inc
For the period ended May 20, 2025. Filed Apr 8, 2025.
View on SEC.govAbout this filing
What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.
May 20, 2025 · Filed Apr 8, 2025
Use the contents to explore the available documents and sections.
Contents
Overview
The term of office of the two Class I directors expires in 2025. Based on the recommendation of our Nominating and Corporate Governance Committee, our Board has nominated Matthew W. Foehr and Charles A. Rowland, Jr. for election to our Board as the Class I directors. If elected at the Annual Meeting, each of Mr. Foehr and Mr. Rowland would serve until the 2028 Annual Meeting of Stockholders and until such director’s respective successor is elected and qualified or, if sooner, until such director’s respective death, resignation or removal. Under this standard, a “plurality” means the two nominees receiving the most “For” votes will be elected to our Board.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.